Fate Therapeutics Announces FDA Clearance of IND Amendment for Clinical Development of PROHEMA
April 23, 2014 at 07:03 AM EDT
Fate Therapeutics, Inc. (Nasdaq: FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell ...
